A network meta-analysis of 15 RCTs evaluating systemic therapy for previously untreated advanced BRAF-mutated melanoma demonstrated that patients treated with BRAF and MEK inhibitors achieved higher ORR compared with BRAF alone (odds ratio of 2.00), and both had superior objective responses compared to other treatments [104]. This evidence concerns the gene MAP2K7 and melanoma.